ADUS Stock Analysis: Buy, Sell, or Hold?
ADUS - Addus HomeCare Corp.
$105.17
2.92 (2.86%)
▲
5d:
+8.58%
30d:
+16.27%
90d:
+12.06%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
29d
Get Alerted When ADUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ADUS is 7.0% above its trading range ($98.27). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ADUS is 7.0% above its trading range ($98.27). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$138.33
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$85.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADUS is currently trading at $105.17, which is considered extended relative to its 30-day fair value range of $90.71 to $98.27. The stock's valuation (Forward PE: 14.1) is in line with its historical norms (14.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This pessimistic expectation contrasts with the company's recent 17.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ADUS is in a downtrend. The price is approaching resistance at $105.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADUS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $132.69 (+26.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADUS is in a downtrend. The price is approaching resistance at $105.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADUS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $132.69 (+26.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$90.71 -
$98.27
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range (+7.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 26.2% below Wall St target ($132.69)
Trading Range Analysis
30-Day Trading Range
$90.71 -
$98.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$93.45
Resistance Level
$105.72
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.07
Wall Street Target
$132.69
(+26.2%)
Revenue Growth (YoY)
7.7%
Earnings Growth (YoY)
17.2%
Profit Margin
6.9%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
14.1 vs 14.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$104.85
(0%)
2-Year Target
$104.54
(-1%)
3-Year Target
$104.23
(-1%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
$105.16
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 6.9%)
$199.06
(+89%)
Base:
(SPY PE: 14.1, Growth: 6.9%)
$128.63
(+22%)
Bear:
(PE: 12.0, Growth: 6.9%)
$109.33
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.87 | Current EPS (TTM): $5.42
Bull Case
$155.08
(+48%)
Analyst growth 37.9%, PE expands to 20.8
Base Case
$140.98
(+34%)
Market implied 37.9%, PE stable at 18.9
Bear Case
$69.53
(-34%)
Severe decline -20.0%, PE contracts to 16.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.1 to 14.2
Stabilization Target:
$106.12
(+0.9%)
PE Expansion Potential:
+0.9%
Share & Embed Analysis
Last updated: July 04, 2026 12:32 AM ET
Data refreshes hourly during market hours. Next update: 1:32 AM
Data refreshes hourly during market hours. Next update: 1:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Cliff Donald Blessing
SELL
178 shares
2026-04-21
Brian Poff
SELL
820 shares
2026-02-25
Cliff Donald Blessing
SELL
177 shares
2026-02-25
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$243 | 57 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$500 | 66 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 58 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 53 HOLD |
|
OPCH
Option Care Health Inc |
STRONG BUY
10 analysts |
$29 | 61 BUY |
